Samsung Biologics Q3 Profit Surges on CDMO Demand
Samsung Biologics posted a strong Q3 2026, with revenue reaching ₩4.07 trillion, fueled by continued growth in its contract development and manufacturing organization (CDMO) business. This represents a substantial increase in demand for outsourced biopharmaceutical manufacturing, highlighting the company’s position as a key player in the sector.
The company’s financial performance reflects a strategic shift toward higher-margin services, and a broader expansion beyond traditional antibody production. Q3 operating profit reached ₩1.81 trillion, demonstrating improved profitability alongside revenue growth. This profitability boost is partially attributable to the recent acquisition of Human Genome Sciences, Inc., adding 60,000 liters of bio-pharmaceutical production capacity in the US, boosting total capacity to 845,000 liters. Samsung Biologics’ capacity now exceeds that of its primary competitors, Lonza, WuXi Biologics, and Fujifilm Biotechnologies.
Looking ahead, Samsung Biologics is actively diversifying its service offerings into next-generation biopharmaceutical areas, including mRNA, antibody-drug conjugates (ADCs), and cell/gene therapies. This ambition is underscored by a recently announced agreement to acquire PolyPeptide Group AG for approximately $1.46 billion (₩1.95 trillion), a move intended to expand the company’s capabilities into the rapidly growing peptide CDMO market. The expansion into these areas reflects a proactive attempt to capture future growth opportunities within the broader biopharmaceutical industry.
The company’s financial results demonstrate a clear strategy of both scaling existing CDMO operations and strategically expanding into adjacent high-growth areas. With a total asset base of ₩12.67 trillion, Samsung Biologics is well-positioned to capitalize on increasing demand for outsourced biopharmaceutical manufacturing, and to continue its trajectory of revenue and profit growth.